Novartis agrees lower price for canakinumab on NHS

NHS England has struck a deal with Novartis to fund a canakinumab, a life-changing fever, headache and painkilling drug for paediatric patients.

Periodic fever syndromes (PFS) are a group of rare genetic conditions where the person’s immune system overreacts, resulting in frequent inflammation ‘flares’, involving chest or joint pains, headaches, mouth ulcers and skin rash.

Although these syndromes only affect a small number of patients, they typically suffer in silence. But now the NHS has confirmed it has struck a deal for the drug, which modifies the immune system, turning off the inflammation process, significantly reducing the number of ‘flares’ children and adults experience.

The deal has been agreed following NHS negotiations with Novartis as part of a major programme to ramp up access to innovative treatments, while freeing up funding for frontline patient care through smarter procurement.

The agreement brings into the NHS a more effective, convenient drug with fewer side effects than existing treatments.

“Some illnesses affect a small number in a big way, which is why the NHS is increasingly bringing innovative, specialised and targeted treatments to people who need them,” said Sir Simon Stevens, Chief Executive of NHS England.

“This latest new treatment has the potential to significantly improve the lives of children who bear the burden of bouts of crippling pain which blights lives and puts strain on families.

“It’s the latest in a line of major deals NHS England has successfully negotiated, which show that when drug companies play ball with the NHS, taxpayers get a fair deal and patients get cutting-edge treatments.”

There are around 168 patients in England with these diseases, both children and adults, and around 80% of these would be prescribed canakinumab.

The discounted price of canakinumab has not been disclosed.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Intravacc & Celonic to develop, produce novel COVID-19 vaccine

Intravacc, a Dutch viral and bacterial vaccine specialist, and Swiss CDMO, Celonic Group, have signed a research agreement to further design, develop and produce...

Tecentriq combination approved for advanced melanoma

The FDA has approved Roche’s Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety...

European approval for Novartis’ Cosentyx in paediatric psoriasis

Novartis has gained European approval for Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years. The...

Hetero cleared to launch first remdesivir generic in India

Hetero, one of India’s leading generic pharmaceutical companies, has received the manufacturing and marketing approval for remdesivir from the Drug Controller General of India...

Collaboration to develop stem cell therapies for COVID-19 and future pandemic diseases

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, has expanded its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. and AffyXell...

Related news

In brief: Sanofi & GSK in talks to supply 300m doses of COVID vaccine to EU

Sanofi and GlaxoSmithKline (GSK) are in “advanced discussions” with the European Commission (EC) for the supply of up to 300 million doses of a...

Intravacc & Celonic to develop, produce novel COVID-19 vaccine

Intravacc, a Dutch viral and bacterial vaccine specialist, and Swiss CDMO, Celonic Group, have signed a research agreement to further design, develop and produce...

Tecentriq combination approved for advanced melanoma

The FDA has approved Roche’s Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety...

European approval for Novartis’ Cosentyx in paediatric psoriasis

Novartis has gained European approval for Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years. The...